Augusta Ortolan
YOU?
Author Swipe
View article: Prediction of 1-Year Activity in Systemic Lupus Erythematosus: Hierarchical Machine Learning Approach
Prediction of 1-Year Activity in Systemic Lupus Erythematosus: Hierarchical Machine Learning Approach Open
Background Systemic lupus erythematosus (SLE) is a chronic disease characterized by a broad spectrum of involved organs, including neurological, renal, and vascular domains, with disease activity manifesting through unpredictable patterns …
View article: Gemelli SLE Data Mart: A Real World Evidence Framework for the Evolution of Systemic Lupus Erythematousus Patients
Gemelli SLE Data Mart: A Real World Evidence Framework for the Evolution of Systemic Lupus Erythematousus Patients Open
The diverse data sources in hospitals are crucial for real-world evidence (RWE) analysis and for developing decision support systems. However, integrating this variety of sources into standardized data collections for a specific disease, r…
View article: Long‐Term Real‐World Safety Profile of Secukinumab Assessed Through a 9‐Year Experience in Patients Affected by Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Results From a Multicentric Retrospective Study
Long‐Term Real‐World Safety Profile of Secukinumab Assessed Through a 9‐Year Experience in Patients Affected by Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Results From a Multicentric Retrospective Study Open
Secukinumab is a biologic agent known for its durable efficacy in chronic plaque psoriasis (PsO), psoriatic arthritis (PsA) and ankylosing spondylitis (AS). Monitoring the safety of secukinumab is a priority to ensure its long‐term usage. …
View article: Phenotype of diffuse cutaneous systemic sclerosis patients with positive anticentromere antibodies: A systematic literature review and meta-analysis
Phenotype of diffuse cutaneous systemic sclerosis patients with positive anticentromere antibodies: A systematic literature review and meta-analysis Open
Although uncommon, the ACA-dcSSc subset appears to have a distinct clinical phenotype, with a better prognosis than ATA-dcSSc.
View article: Sinonasal Outcomes Obtained after 2 Years of Treatment with Benralizumab in Patients with Severe Eosinophilic Asthma and CRSwNP: A “Real-Life” Observational Study
Sinonasal Outcomes Obtained after 2 Years of Treatment with Benralizumab in Patients with Severe Eosinophilic Asthma and CRSwNP: A “Real-Life” Observational Study Open
Background/Objectives: Benralizumab is a monoclonal antibody that targets the interleukin-5 receptor (IL-5Rα), leading to the rapid depletion of blood eosinophils. RCTs have demonstrated efficacy in patients with severe eosinophilic asthma…
View article: A Comprehensive Natural Language Processing Pipeline for the Chronic Lupus Disease
A Comprehensive Natural Language Processing Pipeline for the Chronic Lupus Disease Open
Electronic Health Records (EHRs) contain a wealth of unstructured patient data, making it challenging for physicians to do informed decisions. In this paper, we introduce a Natural Language Processing (NLP) approach for the extraction of t…
View article: Four-year effectiveness, safety and drug retention rate of secukinumab in psoriatic arthritis: a real-life Italian multicenter cohort
Four-year effectiveness, safety and drug retention rate of secukinumab in psoriatic arthritis: a real-life Italian multicenter cohort Open
Objectives to evaluate over a 48-month follow-up period the: 1) long-term effectiveness and safety; 2) drug retention rate (DRR); 3) impact of comorbidities and bDMARDs line on MDA and DAPSA remission/low disease activity (LDA) of secukinu…
View article: Treat-to-target in real-life psoriatic arthritis patients: achieving minimal disease activity with bDMARDs/tsDMARDs and potential barriers
Treat-to-target in real-life psoriatic arthritis patients: achieving minimal disease activity with bDMARDs/tsDMARDs and potential barriers Open
MDA is an attainable target in real-life. AxPsA represents a difficult-to-treat subset. Sustained MDA depends on disease features (axPsA) as well as patients' characteristics (e.g. age, bDMARDs/tDMARDs duration, comorbidities).
View article: AB1388 SEVERE FIBROMYALGIA: DO CENTRAL SENSITIVITY MECHANISMS WORK TOGETHER?
AB1388 SEVERE FIBROMYALGIA: DO CENTRAL SENSITIVITY MECHANISMS WORK TOGETHER? Open
Background Fibromyalgia (FM) is among the most common causes of diffuse chronic pain and falls into the category of central sensitivity syndrome which may be associated with other symptoms such as asthenia, sleep disturbance, bowel and mem…
View article: External validation of the alternative Ankylosing Spondylitis Disease Activity Score in three randomized clinical trials of ixekizumab
External validation of the alternative Ankylosing Spondylitis Disease Activity Score in three randomized clinical trials of ixekizumab Open
Objectives The alternative ASDAS (altASDAS) is an index that can be used when patient global assessment is unavailable. Our aim was to test the truth and discrimination aspects according to OMERACT filter 2.0 of the altASDAS in an external…
View article: Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis
Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis Open
CRD42021257588.
View article: Acute joint swelling in psoriatic arthritis: Flare or “psout”—A 10-year-monocentric study on synovial fluid
Acute joint swelling in psoriatic arthritis: Flare or “psout”—A 10-year-monocentric study on synovial fluid Open
Psoriatic arthritis (PsA) is a multifaceted inflammatory disease associated with psoriasis that can affect peripheral joints, entheses, and the axial skeleton with a variable clinical course. Acute episodes of joint swelling in PsA patient…
View article: Identification in synovial fluid of a new potential pathogenic player in arthropathies
Identification in synovial fluid of a new potential pathogenic player in arthropathies Open
STING (stimulator of interferon genes) has been recognized as an important signaling molecule in the innate immune response to cytosolic nucleic acids. Although it has been proposed that STING signaling pathway may play a pathogenic role i…
View article: Effectiveness and safety of secukinumab in axial spondyloarthritis: a 24-month prospective, multicenter real-life study
Effectiveness and safety of secukinumab in axial spondyloarthritis: a 24-month prospective, multicenter real-life study Open
Objectives: To evaluate, in a multicentric Italian cohort of axial spondyloarthritis (axSpA) patients on Secukinumab (SEC) followed for 24 months: (1) the long-term effectiveness and safety of SEC; (2) the drug retention rate and low disea…